Allogene Therapeutics Inc
allogene.comAllogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biopharmaceutical company developing allogeneic CAR T cell therapies, meaning off-the-shelf cell therapies manufactured from donor cells rather than a patient's own cells. The company generates no product revenue. Its financing has come from equity issuances, including $22.4 million from ATM transactions and $6.9 million from a CIRM award in FY2025, along with prior partnership agreements with Pfizer, Cellectis, and Servier that carry contingent milestone payment obligations. Allogene's pipeline targets hematologic cancers and autoimmune diseases, with lead programs directed at CD19 and CD70 antigens. Key candidates include ALLO-329 for autoimmune indications such as systemic lupus erythematosus, idiopathic inflammatory myopathy, and systemic sclerosis. The company competes against major multinational pharmaceutical companies, established biotechnology firms, and developers of autologous CAR T therapies, all of which generally hold greater financial and manufacturing resources. Allogene was incorporated in Delaware and is headquartered in the United States.
Products & Services
Allogeneic CAR T cell product candidates targeting CD19 and CD70 antigens. ALLO-329 is in development for autoimmune diseases including systemic lupus erythematosus (SLE, estimated 330,000 U.S. diagnosed cases), idiopathic inflammatory myopathy (IIM, estimated 70,000 U.S. diagnosed cases), and systemic sclerosis (SSc, estimated 100,000 U.S. diagnosed cases). A Phase 1b cohort for an anti-CD19/CD70 program has completed enrollment, with further standard dosing paused pending durability results as of the FY2025 10-K filing.
Revenue Model
No product revenue as of the FY2025 10-K filing. Financing has consisted of equity issuances via ATM transactions ($22.4 million in FY2025), a California Institute for Regenerative Medicine (CIRM) award ($6.9 million in FY2025), and employee stock purchase plan proceeds ($0.9 million in FY2025). Future potential revenue is contingent on milestone payments under license agreements with Pfizer, Cellectis, and Servier, tied to development, regulatory, and sales milestones.
Customers & Markets
End markets are patients with relapsed or refractory hematologic cancers and autoimmune diseases, specifically SLE, IIM, and SSc. No commercial customers as of the FY2025 10-K filing. Potential future customers would be hospital systems and oncology or rheumatology treatment centers.
Geographic Exposure
Primary operations in the United States. The company has flagged exposure to U.S. federal trade policy shifts and potential tariffs affecting pharmaceutical ingredients manufactured outside the United States, as noted in the FY2025 10-K filing.
Financial Snapshot
Loading...
